These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9713290)
1. New drugs for prostate cancer? Waxman J; Roylance R Eur J Cancer; 1998 Mar; 34(4):437. PubMed ID: 9713290 [No Abstract] [Full Text] [Related]
2. Prostate cancer drugs. Making sense of the options. Mayo Clin Health Lett; 2003 Aug; 21(8):4-5. PubMed ID: 12971308 [No Abstract] [Full Text] [Related]
3. Choosing a prostate cancer drug. Baker H Br J Nurs; 2014 Sep 11-24; 23(16):S14, S16. PubMed ID: 25203849 [No Abstract] [Full Text] [Related]
4. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. Pitts WR J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434 [No Abstract] [Full Text] [Related]
5. Multiple intracrine hormonal targets in the prostate: opportunities and challenges. Labrie F BJU Int; 2007 Jul; 100 Suppl 2():48-51. PubMed ID: 17594360 [No Abstract] [Full Text] [Related]
6. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis. Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363 [No Abstract] [Full Text] [Related]